- Fully integrated initiative to further CENTOGENE’s reach in U.S. market
- “Patient activation” system to locate parents who have a family history of a neurological genetic condition
- Introducing and providing education on genetic testing, specifically CentoXome®, CENTOGENE’s whole exome sequencing service
Austin, TX – 83bar, the patient activation company, is launching a new initiative in partnership with CENTOGENE, a worldwide leader in the field of genetic diagnostics for rare hereditary diseases.
After recently announcing the opening of its first U.S. based rare disease laboratory in Cambridge, MA, CENTOGENE has enlisted the support of 83bar to reach patients who may benefit from CentoXome®, CENTOGENE’s whole exome sequencing service. CentoXome® offers patients a fast and cost-effective, simple solution which involves sequencing all exons across the genome. Utilizing only 1 μg of DNA easily obtained from a cheek swab, CentoXome® provides patients and physicians with valuable insights when presenting symptoms do not allow a physician to pinpoint a potential diagnosis.
83bar will utilize its proprietary patient activation system to locate parents who have a family history of a neurological genetic condition and whose children are experiencing symptoms that may indicate a neurological genetic condition. The experienced staff of 83bar nurse educators will then help educate, screen, and navigate parents to their nearest pediatric neurologist.
“CENTOGENE is one hundred percent focused on translating rare disease genetics into medical breakthroughs and we are thrilled to continue our global expansion into the preeminent biotech hub of Cambridge,” said Dr. Arndt Rolfs, CEO and founder of CENTOGENE.
“Given the consequences of rare diseases, 83bar is proud to work with CENTOGENE in their efforts meet the need for early diagnosis and treatment options,” said Robert Baurys, president and CEO of 83bar, LLC.
CENTOGENE (www.centogene.com) unlocks the power of genetic insights to improve the quality of life of patients with genetic diseases. We achieve this through knowledge created by our worldwide diagnostic testing services incorporating global diversity, the world’s leading proprietary human genetic interpretation database, CentoMD® and solutions for pharmaceutical companies developing life-changing orphan drugs. As one of the most diversified and largest genetic testing companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients and their families.
83bar, LLC (www.83bar.com), headquartered in Austin, Texas, is the leading patient activation marketing agency. 83bar has developed a system that has been implemented by nearly three dozen name brands in health, medical, technology, and devices. The company has a database of more than 700,000 patient engagements over the past three years.